Brought to you by 
Sanofi launches $69 per share bid for Genzyme; $17.5bn value
04 Sep 2012
Executive Summary
Confirming speculation that began over a month ago, Sanofi-Aventis has made public a non-binding offer to acquire Genzyme Corp. The Big Pharma says it will pay $69 for each of Genzyme's outstanding shares, valuing the deal at about $17.5bn. Genzyme's board was quick to reject the offer, claiming that it dramatically undervalues the company.
Deal Industry
- Pharmaceuticals
-
Medical Devices
- Biomaterials
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sanofi launches $69 per share bid for Genzyme; $17.5bn value
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice